84
Participants
Start Date
November 30, 2009
Primary Completion Date
June 30, 2010
Study Completion Date
June 30, 2010
NN1952
Subjects will be randomised to receive a single dose of NN1952, at escalating dose levels. Progression to next dose will be based on safety evaluation.
insulin aspart
As an active comparator, one standard dose will be given s.c. (under the skin) at all dose levels.
placebo
Subjects will receive a single dose of placebo as a comparator to NN1952, at all dose levels.
NN1952
Subjects will be randomised to receive a single dose of NN1952 with or without a meal, on two of four separate study visits. The dose will be selected based on the results of part 1.
insulin aspart
As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit.
placebo
Subjects will receive a single dose of placebo as a comparator to NN1952 at one study visit.
Novo Nordisk Investigational Site, Neuss
Lead Sponsor
Novo Nordisk A/S
INDUSTRY